RecruitingPhase 2NCT07509892

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

198 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus

Summary

To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.

Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TQH3906 capsule and a drug called TQH3906 placebo for people with systemic lupus erythematosus. The study is currently recruiting participants at 35 locations. People eligible for this study include aged 18 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQH3906 capsule

The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor.

DRUGTQH3906 placebo

Placebo without drug.

Locations(35)

The First Affillated Hospital of Bengbu Medical Universit

Bengbu, Anhui, China

Bozhou People's Hospital

Bozhou, Anhui, China

Beijing Chao-Yang Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Southwest Hospital, Third Military Medical University (Army Medical University)

Chongqing, Chongqing Municipality, China

Gansu Provincial People's Hospital

Lanzhou, Gansu, China

The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Jiangmen Central Hospital

Jiangmen, Guangdong, China

Shenzhen Second People's Hospital

Shenzhen, Guangdong, China

The Second Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

The First Affiliated Hospital Of GuangXi Medical University

Nanning, Guangxi, China

The Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China

Daqing Oilfield General Hospital

Daqing, Heilongjiang, China

Anyang People's Hospital

Anyang, Henan, China

Puyang Oilfield General Hospital

Puyang, Henan, China

Xuchang Central Hospital

Xuchang, Henan, China

The First Affiliated Hospital of Henan University of CM

Zhengzhou, Henan, China

Jingzhou Central Hospital

Jingzhou, Hubei, China

Tongji Hospital Tongji Medical college of HUST

Wuhan, Hubei, China

Yichang Central People's Hospital

Yichang, Hubei, China

Hunan University of Medicine General Hospital

Changsha, Hunan, China

Zhuzhou Central Hospital

Zhuzhou, Hunan, China

Jiansu PeopinceHospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

DAQING OILFIELD GENERAL HOSPITAL DAQING Jilin Provincial People's Hospital

Changchun, Jilin, China

The First Hospital of Jilin University

Changchun, Jilin, China

The First Affiliated Hospital of Air Force Medical University

Xi'an, Shaanxi, China

The Second Affiliated Hospital of Air Force Medical University

Xi'an, Shaanxi, China

Weifang People's Hospital

Weifang, Shandong, China

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

LinFen Central Hospital

Linfen, Shanxi, China

The first People's Hospital of Yibin

Yibin, Sichuan, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Taizhou Central Hospital

Taizhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07509892

Related Trials

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

NCT048334651 location

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325233 locations

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT0691680637 locations

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT0657079857 locations

Study of Systemic Lupus Erythematosus

NCT000013721 location